To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in
patients with HER2-low advanced breast cancer who have received up to one previous
chemotherapy for recurrent or metastatic disease without previous use of antibody-drug
conjugate.